CalciMedica Inc. (CALC)
(Delayed Data from NSDQ)
$5.50 USD
+0.10 (1.85%)
Updated May 21, 2024 02:35 PM ET
2-Buy of 5 2
D Value D Growth A Momentum D VGM
Price, Consensus and EPS Surprise
CALC 5.50 +0.10(1.85%)
Will CALC be a Portfolio Killer in May?
Zacks Investment Research is releasing its prediction for CALC based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Other News for CALC
3 Massively Undervalued 10-Bagger Stocks to Buy
Analysts Offer Insights on Healthcare Companies: CalciMedica (CALC) and GE Healthcare Technologies Inc (GEHC)
CalciMedica GAAP EPS of $0.01
Optimistic Buy Rating for CalciMedica Backed by Strong Financials and Promising Clinical Trials
CalciMedica Reports First Quarter 2024 Financial Results and Provides Clinical & Corporate Updates